Breadcrumb

Beverly  Mock, Ph.D.

Beverly Mock, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute

RESEARCH SUMMARY

Dr. Mock’s genome-wide linkage studies have demonstrated that plasmacytomagenesis is a complex trait, with p16, mTOR and Mndal identified as potential plasmacytoma susceptibility genes. Mouse models of common and rare allelic variants of these genes are being utilized to study their functional differences and identify their roles in tumorigenesis. Combinations of pharmacological inhibitors of these pathways are being evaluated for their synergy in limiting tumor cell growth, and the mechanisms underlying this synergy.

Areas of Expertise

1) mouse genetics 2) B cell neoplasia 3) immunology 4) systems pharmacology 5) tumor suppressors 6) mTOR, MNDA, CDKN2A

Publications

Selected Recent Publications

The transcription factor CBFB suppresses breast cancer through orchestrating translation and transcription

Malik N, Yan H, Moshkovich N, Palangat M, Yang H, Sanchez V, Cai Z, Peat TJ, Jiang S, Liu C, Lee M, Mock BA, Yuspa SH, Larson D, Wakefield LM, Huang J.
Nat Commun. 10(1): 2071, 2019. [ Journal Article ]

Chemical and structural studies provide a mechanistic basis for recognition of the MYC G-quadruplex

Calabrese DR, Chen X, Leon EC, Gaikwad SM, Phyo Z, Hewitt WM, Alden S, Hilimire TA, He F, Michalowski AM, Simmons JK, Saunders LB, Zhang S, Connors D, Walters KJ, Mock BA, Schneekloth JS Jr.
Nat Commun. 9(1): 4229, 2018. [ Journal Article ]

Characterization of clinically used oral antiseptics as quadruplex-binding ligands

Calabrese DR, Zlotkowski K, Alden S, Hewitt WM, Connelly CM, Wilson RM, Gaikwad S, Chen L, Guha R, Thomas CJ, Mock BA, Schneekloth JS Jr.
Nucleic Acids Res. 46(6): 2722-32, 2018. [ Journal Article ]

Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy

Eiden AM, Zhang S, Gary JM, Simmons JK, Mock BA.
Clin Cancer Res. 22(2): 277-83, 2016. [ Journal Article ]

Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity

Ou O, Huppi K, Chakka S, Gehlhaus K, Dubois W, Patel J, Chen J, Mackiewicz M, Jones TL, Pitt JJ, Martin SE, Goldsmith P, Simmons JK, Mock BA, Caplen NJ.
Cancer Lett. 354(2): 336-47, 2014. [ Journal Article ]

Job Vacancies

There are no open positions at this time. Check back again later, or take a look at CCR's Careers page.

Team

Postdoctoral Fellow (Visiting)
Snehal Gaikwad, Ph.D.
Postdoctoral Fellow (CRTA)
Vincent Hughitt, Ph.D.
Research Biologist
Ke Zhang, Ph.D.
Clinical Fellow
Joe Nguyen, D.D.S., Ph.D.
Postbaccalaureate Fellow (CRI)
Nana Gyabaah-Kessie
Postbaccalaureate Fellow (iCURE)
Nahid Anna Savan
Postbaccalaureate Fellow (CRTA)
Rohini Guin
Postbaccalaureate Fellow (CRTA)
Mikaela Matera-Vatnick